Log in

Adaptimmune Therapeutics Short Interest Ratio and Short Volume

+0.50 (+11.63 %)
(As of 10/23/2020 12:00 AM ET)
Today's Range
Now: $4.80
50-Day Range
MA: $8.07
52-Week Range
Now: $4.80
Volume3.78 million shs
Average Volume1.14 million shs
Market Capitalization$624.53 million
P/E RatioN/A
Dividend YieldN/A

Short Interest

Adaptimmune Therapeutics (NASDAQ:ADAP) Short Interest Data

Current Short Volume:5,320,000 shares
Previous Short Volume:4,900,000 shares
Change Vs. Previous Month:+8.57%
Dollar Volume Sold Short:$48.94 million
Short Interest Ratio / Days to Cover:8.0
Last Record Date:September, 30 2020
Outstanding Shares:104,710,000 shares
Short Percent of Float:0.00%
Today's Trading Volume:3,784,802 shares
Average Trading Volume:1,140,823 shares
Today's Volume Vs. Average:231.76%

Adaptimmune Therapeutics (NASDAQ:ADAP) Short Interest History

DateShares Sold ShortDollar Volume Sold ShortPercentage ChangePercentage FloatDays to CoverPrice on Record Date
9/30/20205,320,000 $48.94 million 8.6%0.0%7.5$9.20
9/15/20204,900,000 $38.56 million 50.8%0.0%6.3$7.87
8/31/20203,250,000 $26.46 million -18.8%0.0%4.1$8.14
8/14/20204,000,000 $34.08 million 2.8%0.0%1.3$8.52
7/31/20203,890,000 $33.53 million 3.5%0.0%1.2$8.62
7/15/20203,760,000 $35.16 million 1.1%0.0%1.2$9.35
6/30/20203,720,000 $32.74 million -5.6%0.0%1.2$8.80
6/15/20203,940,000 $38.93 million 605.1%0.0%1.3$9.88
5/29/2020558,800 $5.36 million 39.4%0.0%0.2$9.59
5/15/2020401,000 $4.44 million -45.2%0.0%0.7$11.07
4/30/2020731,400 $3.50 million -10.0%0.0%1.6$4.78
4/15/2020812,400 $3.71 million 14.7%0.9%1.6$4.57
3/31/2020708,600 $2.44 million 70.5%0.8%0.4$3.45
3/13/2020415,600 $1.25 million -11.4%0.5%1.1$3.01
2/28/2020468,800 $1.32 million -28.2%0.5%0.2$2.81
2/14/2020653,000 $2.00 million 11.8%0.7%0.3$3.06
1/31/2020584,100 $2.05 million -66.4%0.7%0.3$3.51
1/15/20201,740,000 $7.24 million 13.7%2.0%0.9$4.16
12/31/20191,530,000 $6.00 million -35.2%1.7%1$3.92
8/15/20193,798,400 $5.43 million 4.7%4.4%13$1.43

Adaptimmune Therapeutics (NASDAQ:ADAP) Short Interest FAQ

speech bubbles
speech bubbles

What is Adaptimmune Therapeutics' current short interest?

Short interest is the volume of Adaptimmune Therapeutics shares that have been sold short but have not yet been covered or closed out. As of September 30th, traders have sold 5,320,000 shares of ADAP short. 0.00% of Adaptimmune Therapeutics' shares are currently sold short. View details.

What is a good short interest ratio for Adaptimmune Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Adaptimmune Therapeutics currently has a short interest ratio of 8.0.

Is Adaptimmune Therapeutics' short interest increasing or decreasing?

Adaptimmune Therapeutics saw a increase in short interest in September. As of September 30th, there was short interest totaling 5,320,000 shares, an increase of 8.6% from the previous total of 4,900,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Adaptimmune Therapeutics' short interest compare to its competitors?

0.00% of Adaptimmune Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Adaptimmune Therapeutics: Sorrento Therapeutics Inc (0.00%), Editas Medicine Inc (0.00%), Replimune Group Inc (4.77%), Bavarian Nordic A/S (0.00%), Sangamo Therapeutics Inc (0.00%), Cortexyme, Inc. (13.89%), NanoString Technologies, Inc. (0.00%), Mesoblast limited (0.00%), Coherus Biosciences Inc (26.54%), and Atara Biotherapeutics, Inc. (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications Inc ($5.12 billion), Aon PLC ($3.76 billion), Clorox Co ($3.07 billion), ViacomCBS Inc. ($2.89 billion), Analog Devices, Inc. ($2.49 billion), Moderna, Inc. ($2.37 billion), Datadog, Inc. ($2.29 billion), Uber Technologies, Inc. ($2.22 billion), Kroger Co ($2.20 billion), and Simon Property Group, Inc. ($1.88 billion). View all of the most shorted stocks.

What does it mean to sell short Adaptimmune Therapeutics stock?

Short selling ADAP is an investing strategy that aims to generate trading profit from Adaptimmune Therapeutics as its price is falling. Adaptimmune Therapeutics' stock is trading up $0.50 today. To short Adaptimmune Therapeutics stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Adaptimmune Therapeutics will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Adaptimmune Therapeutics?

A short squeeze for Adaptimmune Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ADAP, which in turn drives the price of the stock up even further.

How often is Adaptimmune Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ADAP, twice per month. The most recent reporting period available is September, 30 2020.

This page was last updated on 10/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.